Amish N Raval1, Eric G Schmuck2, Girma Tefera3, Cathlyn Leitzke2, Cassondra Vander Ark2, Derek Hei4, John M Centanni2, Ranil de Silva5, Jill Koch2, Richard G Chappell6, Peiman Hematti7. 1. Division of Cardiovascular Medicine, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA. Electronic address: anr@medicine.wisc.edu. 2. Division of Cardiovascular Medicine, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA. 3. Division of Vascular Surgery, Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA. 4. Waisman Biomanufacturing Facility, Madison, Wisconsin, USA. 5. National Heart and Lung Institute, Imperial College London and NIHR Cardiovascular Biomedical Research Unit, Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom. 6. Department of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA. 7. Division of Hematology/Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Abstract
BACKGROUND AIMS: CD133+ cells confer angiogenic potential and may be beneficial for the treatment of critical limb ischemia (CLI). However, patient selection, blinding methods and end points for clinical trials are challenging. We hypothesized that bilateral intramuscular administration of cytokine-mobilized CD133+ cells in ambulatory patients with refractory CLI would be feasible and safe. METHODS: In this double-blind, randomized sham-controlled trial, subjects received subcutaneous injections of granulocyte colony-stimulating factor (10 μg/kg per day) for 5 days, followed by leukapheresis, and intramuscular administration of 50-400 million sorted CD133+ cells delivered into both legs. Control subjects received normal saline injections, sham leukapheresis and intramuscular injection of placebo buffered solution. Subjects were followed for 1 year. An aliquot of CD133+ cells was collected from each subject to test for genes associated with cell senescence. RESULTS:Seventy subjects were screened, of whom 10 were eligible. Subject enrollment was suspended because of a high rate of mobilization failure in subjects randomly assigned to treatment. Of 10 subjects enrolled (7 randomly assigned to treatment, 3 randomly assigned to control), there were no differences in serious adverse events at 12 months, and blinding was preserved. There were non-significant trends toward improved amputation-free survival, 6-minute walk distance, walking impairment questionnaire and quality of life in subjects randomly assigned to treatment. Successful CD133+ mobilizers expressed fewer senescence-associated genes compared with poor mobilizers. CONCLUSIONS:Bilateral administration of autologous CD133+ cells in ambulatory CLI subjects was safe, and blinding was preserved. However, poor mobilization efficiency combined with high CD133+ senescence suggests futility in this approach.
RCT Entities:
BACKGROUND AIMS: CD133+ cells confer angiogenic potential and may be beneficial for the treatment of critical limb ischemia (CLI). However, patient selection, blinding methods and end points for clinical trials are challenging. We hypothesized that bilateral intramuscular administration of cytokine-mobilized CD133+ cells in ambulatory patients with refractory CLI would be feasible and safe. METHODS: In this double-blind, randomized sham-controlled trial, subjects received subcutaneous injections of granulocyte colony-stimulating factor (10 μg/kg per day) for 5 days, followed by leukapheresis, and intramuscular administration of 50-400 million sorted CD133+ cells delivered into both legs. Control subjects received normal saline injections, sham leukapheresis and intramuscular injection of placebo buffered solution. Subjects were followed for 1 year. An aliquot of CD133+ cells was collected from each subject to test for genes associated with cell senescence. RESULTS: Seventy subjects were screened, of whom 10 were eligible. Subject enrollment was suspended because of a high rate of mobilization failure in subjects randomly assigned to treatment. Of 10 subjects enrolled (7 randomly assigned to treatment, 3 randomly assigned to control), there were no differences in serious adverse events at 12 months, and blinding was preserved. There were non-significant trends toward improved amputation-free survival, 6-minute walk distance, walking impairment questionnaire and quality of life in subjects randomly assigned to treatment. Successful CD133+ mobilizers expressed fewer senescence-associated genes compared with poor mobilizers. CONCLUSIONS: Bilateral administration of autologous CD133+ cells in ambulatory CLI subjects was safe, and blinding was preserved. However, poor mobilization efficiency combined with high CD133+ senescence suggests futility in this approach.
Authors: M Vasa; S Fichtlscherer; A Aicher; K Adler; C Urbich; H Martin; A M Zeiher; S Dimmeler Journal: Circ Res Date: 2001-07-06 Impact factor: 17.367
Authors: U M Gehling; S Ergün; U Schumacher; C Wagener; K Pantel; M Otte; G Schuch; P Schafhausen; T Mende; N Kilic; K Kluge; B Schäfer; D K Hossfeld; W Fiedler Journal: Blood Date: 2000-05-15 Impact factor: 22.113
Authors: Martin Teraa; Ralf W Sprengers; Yolanda van der Graaf; Charmaine E J Peters; Frans L Moll; Marianne C Verhaar Journal: Ann Surg Date: 2013-12 Impact factor: 12.969
Authors: E Bernd Ringelstein; Vincent Thijs; Bo Norrving; Angel Chamorro; Franz Aichner; Martin Grond; Jeff Saver; Rico Laage; Armin Schneider; Frank Rathgeb; Gerhard Vogt; Gabriele Charissé; Jochen B Fiebach; Stefan Schwab; Wolf R Schäbitz; Rainer Kollmar; Marc Fisher; Miroslav Brozman; David Skoloudik; Franz Gruber; Joaquin Serena Leal; Roland Veltkamp; Martin Köhrmann; Jörg Berrouschot Journal: Stroke Date: 2013-08-20 Impact factor: 7.914
Authors: Joseph Poole; Kreton Mavromatis; José N Binongo; Ali Khan; Qunna Li; Mohamed Khayata; Elizabeth Rocco; Matthew Topel; Xin Zhang; Charlene Brown; Matthew A Corriere; Jonathan Murrow; Salman Sher; Stephanie Clement; Khuram Ashraf; Amr Rashed; Tarek Kabbany; Robert Neuman; Alanna Morris; Arshad Ali; Salim Hayek; John Oshinski; Young-sup Yoon; Edmund K Waller; Arshed A Quyyumi Journal: JAMA Date: 2013-12-25 Impact factor: 157.335
Authors: S Fadilah Abdul Wahid; Nor Azimah Ismail; Wan Fariza Wan Jamaludin; Nor Asiah Muhamad; Muhammad Khairul Azaham Abdul Hamid; Hanafiah Harunarashid; Nai Ming Lai Journal: Cochrane Database Syst Rev Date: 2018-08-29
Authors: Paula Müller; Natalia Voronina; Frauke Hausburg; Cornelia A Lux; Frank Wiekhorst; Gustav Steinhoff; Robert David Journal: Stem Cells Int Date: 2016-10-04 Impact factor: 5.443